Related Experiment Video
Updated: Jun 1, 2025

High-resolution Respirometry to Measure Mitochondrial Function of Intact Beta Cells in the Presence of Natural Compounds
Published on: January 23, 2018
Investigating GLP-1 Injections: Potential Mitochondrial Dysfunction in Non-Diabetic Patients Presenting with
Jana Jamail1, Rachel Knowles2, Leslie Fuller3
1Certified Nutritional Consultant, Certified Plant-Based Nutrition, Certified Wellness Counseling. Human Nutrition and Functional Medicine Masters Alumnus, University of Western States, CEO and Founder of Rose+Ginger Nutrition, Austin, Texas, USA.
Introduction:
GLP-1 medications are widely used for weight loss in patients with and without type 2 diabetes. However, limited research exists on their effects in non-diabetic patients, particularly concerning mitochondrial function. This case report investigates the potential of altered mitochondrial dysfunction as a cause of side effects of GLP-1 medications in patients without type 2 diabetes.
Case Presentation:
The patient, a 43-year-old female with a BMI of 32, presented with hypoglycemia and persistent migraines with auras after Ozempic and Mounjaro injections.
Outcomes:
The patient changed her diet to include 90 grams of protein and frequent small meals throughout the day. She took CoQ10, D-ribose, vitamin B complex, and acetyl-l-carnitine, to address the migraines, and this also improved the mitochondrial function. The patient reported balanced blood sugar after changing her diet; her migraines improved and did not return after taking supplementation.
Conclusion:
This case report emphasizes the need for awareness and monitoring of potential mitochondrial side effects from GLP-1 injections in patients without type 2 diabetes. Nutritional and supplemental interventions effectively managed the patient's symptoms and emphasized the need for tailored interventions in patients using GLP-1 medications. Further research is needed to understand how GLP-1 injections impact mitochondrial function.
Related Concept Videos
Hypoglycemia and Glucagon
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: Glinides
Oral Hypoglycemic Agents: Biguanides and Glitazones
Diabetes Mellitus: Type 2 and Gestational

